Compare · CELZ vs MCO
CELZ vs MCO
Side-by-side comparison of Creative Medical Technology Holdings Inc. (CELZ) and Moody's Corporation (MCO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CELZ and MCO operate in Finance: Consumer Services (Finance), so they compete in similar markets.
- MCO is the larger of the two at $83.78B, about 13492.1x CELZ ($6.2M).
- MCO has been more active in the news (8 items in the past 4 weeks vs 2 for CELZ).
- MCO has more recent analyst coverage (25 ratings vs 1 for CELZ).
Creative Medical Technology Holdings Inc.
Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem for the treatment of erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine for the treatment of chronic lower back pain; Amniostem for the treatment of strokes, radiation, toxicity, and glioma; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. was incorporated in 1998 and is based in Phoenix, Arizona.
Moody's Corporation
Moody's Corporation operates as an integrated risk assessment firm worldwide. It operates in two segments, Moody's Investors Service and Moody's Analytics. The Moody's Investors Service segment publishes credit ratings and provides assessment services on various debt obligations, programs and facilities, and entities that issue such obligations, such as various corporate, financial institution, and governmental obligations; and structured finance securities. This segment provides ratings in approximately 140 countries. Its ratings are disseminated through press releases to the public through electronic media, including the internet and real-time information systems used by securities traders and investors. This segment has rated approximately 5,000 non-financial corporates; 3,600 financial institutions; 16,000 public finance issuers; 145 sovereigns; 47 supranational institutions; 459 sub-sovereigns; and 1,000 infrastructure and project finance issuers, as well as 9,100 structured finance deals. The Moody's Analytics segment develops a range of products and services that support the risk management activities of institutional participants in financial markets; and offers subscription based research, data, and analytical products comprising credit ratings, credit research, quantitative credit scores and other analytical tools, economic research and forecasts, business intelligence and company information products, commercial real estate data and analytical tools, and on-line and classroom-based training services, as well as credentialing and certification services. It also offers software solutions, as well as related risk management services; and offshore analytical and research services with learning solutions and certification programs. The company was formerly known as Dun and Bradstreet Company and changed its name to Moody's Corporation in September 2000. Moody's Corporation was founded in 1900 and is headquartered in New York, New York.
Latest CELZ
- President & CEO Warbington Timothy was granted 1,000,000 shares (SEC Form 4)
- Creative Medical Technology Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent Filing
- Creative Medical Technology Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning
- SEC Form 10-Q filed by Creative Medical Technology Holdings Inc.
- Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms
- SEC Form 424B3 filed by Creative Medical Technology Holdings Inc.
- SEC Form EFFECT filed by Creative Medical Technology Holdings Inc.
- SEC Form S-3 filed by Creative Medical Technology Holdings Inc.
Latest MCO
- Amendment: SEC Form 8-K/A filed by Moody's Corporation
- SEC Form 4 filed by Moody's Corporation
- Chief Acctg Off & Controller Phillips Jason D covered exercise/tax liability with 21 shares, decreasing direct ownership by 1% to 2,088 units (SEC Form 4)
- President and CEO Fauber Robert sold $419,965 worth of shares (923 units at $455.00) as part of a pre-agreed trading plan and exercised 623 shares at a strike of $163.07, decreasing direct ownership by 0.58% to 51,364 units (SEC Form 4)
- Moody’s Analytics and Allvue Launch Credit Risk Model to Identify Early Signs of Borrower Stress in Private Credit
- HealthEquity Appoints Moody’s CFO Noémie Heuland to Board of Directors
- Date Set For Moody's Earnings Release And Investor Teleconference
- Moody's Named #1 in Chartis RiskTech100® for Fifth Consecutive Year
- Moody’s to Acquire Minority Stake in Philippine Rating Services Corporation (PhilRatings)
- Director Van Saun Bruce was granted 20 shares, increasing direct ownership by 0.21% to 9,901 units (SEC Form 4)